Abstract
In the last few years high-dose chemotherapy expanded throughout Europe as a treatment option for breast carcinoma patients. In 1993, 400 patients were reported during the annual European survey, while in 1996 more than 2100 patients received this treatment modality, and we may foresee that at least 2500 women underwent this procedure in 1998. From the European Group for Blood and Marrow Transplantation (EBMT) Registry data base more than 95% of the high-dose programs have been conducted with the support of Peripheral Blood Progenitor Cells (PBPC) last year, with a minority of patients receiving Autologous Bone Marrow Transplantation (ABMT) as hematopoietic support. This data are slightly different from those recently reported by the Autologous Bone Marrow Transplantation Registry of North America,1 indicating that 25% of the patients received ABMT, alone or in combination with PBPC (data referring to 1995). Patients selected for high-dose chemotherapy programs are equally divided into metastatic and adjuvant ones, with 10% with inflammatory breast carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Antman KH, Rowlings PA, Vaughan WA, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15: 1302, 1997.
Rosti G, Ferrante P, Philip T, Marangolo M. High-dose chemotherapy (HDC) for solid tumors in Europe: a survey by the European Group for Blood and Marrow Transplantation (EBMT). J Clin Oncol 14: 968a, 1996.
Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC, Jr., Jones R, Shpall EJ, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB, Budman D, Hurd D. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11: 1131, 1993.
Gianni AM, Siena S, Bregni M, Di Nicola M, Orefice S, Cusumano F, Salvadori B, Luini A, Greco M, Zucali R, Rilke F, Zambetti M, Valagussa P, Bonadonna G. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 15: 2312, 1997.
Ayash LF, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, Schipper L, Antman KH, Frei E, III, Elias AD. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy for advanced breast cancer. J Clin Oncol 13: 2043, 1995.
Goldman JM, Schmitz N, Niethammer D, Gratwohl A. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disoredrs: current practice in Europe in 1998. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21: 1–7, 1998.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rosti, G. et al. (1999). High-Dose Chemotherapy for Breast Cancer in Europe. In: Abraham, N.G., Tabilio, A., Martelli, M., Asano, S., Donfrancesco, A. (eds) Molecular Biology of Hematopoiesis 6. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4797-6_19
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4797-6_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7173-1
Online ISBN: 978-1-4615-4797-6
eBook Packages: Springer Book Archive